Graduate Spotlight: Dr. Rashid Kazerooni, Botulinum Toxin Type A Overdoses

Dr. Rashid Kazerooni, PharmD, MS, BCPS, is a Medical Science Liaison at Merz North America. Dr. Kazerooni is among the first graduates of the University of Wyoming’s 2016-2018 MSHSA program and we couldn’t more proud of his independent project, Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database, being published.

_______________________________________________________________________________________

© Springer International Publishing AG, part of Springer Nature 2018

Introduction

Published literature on overdoses related to botulinum toxin A (BtxA) agents is scarce.

Objective

The aim of this study was to assess the BtxA drug class’ respective agents for associations with overdose.

Methods

United States Food and Drug Administration (FDA) adverse event reporting system (FAERS) database was utilized to search for overdoses. The analysis was conducted on data between second quarter 2014 and third quarter 2017. BtxA cases were included when they were considered the “Primary Suspect” drug. Overdose was defined as presence of ‘overdose’ being reported as an adverse event. Primary outcome was incidence of ‘overdose’ compared within the respective agents. Additionally, a disproportionality analysis was conducted utilizing reporting odds ratio (ROR) versus onabotulinumtoxinA as a referent while controlling for confounding variables.

The full study is published and can be purchased from Springer International Publishing, click here.

Results

A total of 3,837,406 unique adverse events were reported during the study period for all drugs in the FAERS database. Of which, 13,078 were BtxA cases. The rate of adverse events involving overdose for abobotulinumtoxinA (20.2%; 215/1065) was significantly higher than both onabotulinumtoxinA (0.4%; 48/11,323; p < 0.0001) and incobotulinumtoxinA (0.1%; 1/690; p < 0.0001). In the regression analysis, abobotulinumtoxinA (ROR 73.26; 95% CI 51.17–104.90) had a significant association with overdose, whereas incobotulinumtoxinA (ROR 0.73; 95% CI 0.10–5.36) did not, versus the referent onabotulinumtoxinA.

Conclusion

The present analysis showed adverse events of abobotulinumtoxinA were significantly associated with overdose versus the other two BtxA agents. Overdose can be difficult to research, particularly for in-clinic administered drugs. Future studies should venture to confirm these results in new and novel ways.

© Springer International Publishing AG, part of Springer Nature 2018

References:

  1. Ubbink DT, Santema TB, Lapid O. Shared decision-making in cosmetic medicine and aesthetic surgery. Aesthet Surg J. 2016;36(1):NP14-9.CrossRefPubMedGoogle Scholar
  2. Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. J Clin Aesthet Dermatol. 2014;7(2):31–9.PubMedPubMedCentralGoogle Scholar
  3. Allergan, Inc. Botox® (onabotulinumtoxinA) prescribing information. 2018. https://www.allergan.com/assets/pdf/botox_pi.pdf. Accessed 10 Mar 2018.
  4. Allergan, Inc. Botox Cosmetic® (onabotulinumtoxinA) prescribing information. 2018. https://www.allergan.com/assets/pdf/botox_cosmetic_pi.pdf. Accessed 10 Mar 2018.
  5. Ipsen Biopharm Ltd. Dysport® (abobotulinumtoxinA) prescribing information. 2018. https://www.dysport.com/docs/pdfs/Dysport_Full_Prescribing_Information.pdf. Accessed 10 Mar 2018.
  6. Merz North America, Inc. Xeomin® (incobotulinumtoxinA) prescribing information. 2018. http://www.xeomin.com/wp-content/uploads/xeomin-full-prescribing-information.pdf. Accessed 10 Mar 2018.
  7. Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf. 2001;10:407–10.CrossRefPubMedGoogle Scholar
  8. Fadini GP, Sarangdhar M, Avogaro A. Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA adverse event reporting system. BMJ Open Diabetes Res Care. 2018;6(1):e000475.CrossRefPubMedPubMedCentralGoogle Scholar
  9. US FDA. FDA adverse event reporting system (FAERS): Latest quarterly data files. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082193.htm. Accessed 10 Mar 2018.
  10. MedDRA. https://www.meddra.org/. Accessed 10 Mar 2018.
  11. Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427–36.CrossRefPubMedGoogle Scholar
  13. 14.
    Hauben M, Reich L. Drug-induced pancreatitis: lessons in data mining. Br J Clin Pharmacol. 2004;58:560–2 [PMC free article].CrossRefPubMedPubMedCentralGoogle Scholar
  14. Almenoff J, Tonning JM, Gould AL, et al. Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf. 2005;28:981–1007.CrossRefPubMedGoogle Scholar
  15. Almenoff JS, Pattishall EN, Gibbs TG, et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007;82:157–66.CrossRefPubMedGoogle Scholar
  16. Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today. 2009;14:343–57.CrossRefPubMedGoogle Scholar
  17. Humphrey S. Neurotoxins: evidence for prevention. J Drugs Dermatol. 2017;16(6):s87–90.PubMedGoogle Scholar
  18. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med. 1993;118:201–10.CrossRefPubMedGoogle Scholar
  19. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64(11):1949–51.CrossRefPubMedGoogle Scholar
  20. Roggenkämper P, Jost WH, Bihari K, Comes G, Grafe S, NT 201 Blepharospasm Study Team. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm (Vienna). 2006;113(3):303–12.CrossRefGoogle Scholar
  21. Kane MA, Gold MH, Coleman WP 3rd, Jones DH, Tanghetti EA, Alster TS, Rohrer TE, Burgess CM, Shamban AT, Finn E. A Randomized, double-blind trial to investigate the equivalence of incobotulinumtoxinA and onabotulinumtoxinA for glabellar frown lines. Dermatol Surg. 2015;41(11):1310–9.CrossRefPubMedGoogle Scholar
  22. Sattler G, Callander MJ, Grablowitz D, Walker T, Bee EK, Rzany B, Flynn TC, Carruthers A. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg. 2010;36(Suppl 4):2146–54.CrossRefPubMedGoogle Scholar
  23. Nüssgens Z, Roggenkämper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 1997;235:197–9.CrossRefPubMedGoogle Scholar
  24. Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. Eur J Neurol. 2009;16(3):392–8.CrossRefPubMedGoogle Scholar
  25. Kerscher M, Roll S, Becker A, Wigger-Alberti W. Comparison of the spread of three botulinum toxin type A preparations. Arch Dermatol Res. 2012;304(2):155–61.CrossRefPubMedGoogle Scholar
  26. 27.
    Weber J. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. Adv Inflamm Res. 1984;6:1–7.Google Scholar
  27. Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM. The Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014;37:283–94.CrossRefPubMedPubMedCentralGoogle Scholar
  28. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519–23.CrossRefPubMedGoogle Scholar
  29. US FDA. FDA adverse event reporting system (FAERS) public dashboard. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070093.htm. Accessed 10 Mar 2018.

 

 

 

How to Choose a Master’s Degree Program

Choosing a Master’s Degree program requires some research, with an understanding of what you want to do with your future and why you believe a Master’s Degree will assist you in that pursuit. Leaders with specialized healthcare expertise are in demand, and according to the recently released Bureau of Labor Statistics report, the pharmacy profession is only expected to grow incrementally between now and 2026, but Healthcare Administration is growing at a much faster than average rate.

If you are serious about getting a Master’s Degree in the healthcare industry, do your homework and learn all you can about a school before you apply. Ask questions. Compare schools to find the best fit for you and the future you want.

As cliché as it is, you have endless options when it comes to choosing a Master’s Degree program. Filtering through the options can be an taxing chore, so the following are questions that can assist you in finding the best option for you.

What Are the Admission Requirements?

If you had some wild nights and not so stellar grades in your undergraduate courses and your grade point average does not meet the minimum requirements for admission to a graduate-level school or program, keep looking. Many colleges and universities will factor in your work experience and the fact that you have matured since your college days. A meticulously completed application, a resume that shows a growing career, a personal statement outlining your experience in the pharmaceutical or healthcare field, and excellent letters of recommendation should help you get accepted by an institution that meets your needs. In fact, graduate schools often provide provisional admission.

How Much Will It Cost?

For most, cost is a major consideration when deciding on a program. Graduate students often pay for tuition and fees out-of-pocket. However, the number of highly-regarded, accredited schools that offer online Master’s Degree programs has grown over the years. “The University of Wyoming may be the only program on this online master’s degree in health services administration ranking to actually undercut Mississippi College on tuition costs,” TMHA Staff. It is possible to reduce some costs of attending graduate school by completing the work online. At the University of Wyoming, we also offer discounts to folks that have served or are currently serving in the military and those that are registered with our affiliate programs like the Wyoming Pharmacy Association. While some private college online programs may be out of your price range, many state universities offer comparable Master’s Degrees online. An advantage to studying online is the flexibility of the classes and assignments to fit into your family life and current work life, and many even can continue to work full-time while earning the degree.

New to accreditation?

If you are going to invest your time and money in getting a Master’s Degree, do your homework and make sure that the university you choose is accredited. An accredited school is one that has been assessed by a regional or state accrediting agency and determined to meet certain standards of quality. Those accreditation agencies must be approved by the U.S. Department of Education, which also maintains a database of accredited colleges and universities.

Choosing an accredited institution is important because accredited schools that remain in good standing can administer federal financial aid programs. Employers also typically prefer applicants with degrees from accredited institutions.

Does the school have a good reputation?

Research the reputation of a school before you apply. Even if the school is accredited, you want to know if there have been any issues. Has accreditation ever been in jeopardy? Does the department in which you will seek your Master’s Degree have a good track record of preparing students to get better jobs or pursue a PhDs or other terminal degrees?

How Long Will It Take to Earn the Degree?

If you choose a master’s degree in your undergraduate field, you may be able to complete your degree in as little as one year. If you’ll be getting a degree in a new field, it may take two years of full-time study, and with part-time study, it could take three to four years to earn your degree. Our program is just two years long and can be stretched into six if you desire.

Should I Choose an Online Program?

Whether you choose an online or campus-based program depends on how you learn, where you and the school are located, and where you are at in your personal life. Our entire program is online, with two required in-person seminars in Laramie, WY throughout the 5 semesters. Many of our successful graduates have highly rated the convenience of the online classes and the ease of meeting within the time frame as required.